A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

Manufacturers are investing in key recombinant vaccines and improving product pipelines, driving growth in the market.

Registration is open for faculty to attend the Westwood Lecture Series on Jan. 28. Suresh Mittal, Distinguished Professor of Virology in the College of Veterinary Medicine, will present ...

Inactivated virus, viral vector, bacterial vector, subunit and DNA vaccines encoding several antigens have been developed and shown to be immunogenic. Vaccine trials in animal models that mimic ...

2 Recombinant AAV is being used increasingly ... standardization of measurements for AAV in the context of viral vector–based gene therapies, the authors concluded. The study acknowledged ...

COVID-19 [adenovirus type 5] vaccine (Convidecia) is an recombinant adenovirus type 5 vector vaccine. It is formulated as suspension and solution for intramuscular route and solution for inhalational ...

The recombinant virus MVA-SARS-2-S was constructed and characterized in detail as described elsewhere (50). In the present study, a quality controlled vaccine lot was applied serving for preclinical ...

Around the same time, a senior in Louisiana was diagnosed with the first "severe" case in the U.S. As bird flu continues to ramp up, many are wondering what tools—namely, vaccines—we have to ...

The authors explored the impact of IGFBP7 on cardiomyocytes by initially inducing IGFBP7 overexpression in the heart using an AAV9 vector. The hearts with IGFBP7 ... 7 Katoh et al developed an ...

Today it is driving efforts to create a new generation of therapies known as “cancer vaccines” that aim to train the immune system to recognise tumours and fight their spread. Trials are now ...